Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.31
OMBP's Cash to Debt is ranked lower than
126% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. OMBP: 0.31 )
Ranked among companies with meaningful Cash to Debt only.
OMBP' s 10-Year Cash to Debt Range
Min: 0.06  Med: 41.58 Max: No Debt
Current: 0.31
F-Score: 1
Z-Score: -79.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROA (%) -433.70
OMBP's ROA (%) is ranked lower than
125% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. OMBP: -433.70 )
Ranked among companies with meaningful ROA (%) only.
OMBP' s 10-Year ROA (%) Range
Min: -1355.56  Med: -597.24 Max: -420.9
Current: -433.7
-1355.56
-420.9
ROC (Joel Greenblatt) (%) -43612.50
OMBP's ROC (Joel Greenblatt) (%) is ranked lower than
130% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. OMBP: -43612.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMBP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1645400  Med: -866133.33 Max: -199300
Current: -43612.5
-1645400
-199300
EBITDA Growth (3Y)(%) -40.90
OMBP's EBITDA Growth (3Y)(%) is ranked lower than
249% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. OMBP: -40.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OMBP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -3.05 Max: 152
Current: -40.9
0
152
EPS Growth (3Y)(%) -37.70
OMBP's EPS Growth (3Y)(%) is ranked lower than
258% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. OMBP: -37.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OMBP' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -19.30 Max: 168.4
Current: -37.7
0
168.4
» OMBP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OMBP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Current Ratio 0.58
OMBP's Current Ratio is ranked lower than
131% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. OMBP: 0.58 )
Ranked among companies with meaningful Current Ratio only.
OMBP' s 10-Year Current Ratio Range
Min: 0.1  Med: 2.72 Max: 15.13
Current: 0.58
0.1
15.13
Quick Ratio 0.58
OMBP's Quick Ratio is ranked lower than
131% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. OMBP: 0.58 )
Ranked among companies with meaningful Quick Ratio only.
OMBP' s 10-Year Quick Ratio Range
Min: 0.1  Med: 2.72 Max: 15.13
Current: 0.58
0.1
15.13

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -135.10
OMBP's Earnings Yield (Greenblatt) (%) is ranked lower than
130% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. OMBP: -135.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OMBP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -151.5  Med: 0.00 Max: 0
Current: -135.1
-151.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Omni Bio Pharmaceutical Inc was incorporated under the name of Across America Financial Services, Inc. On March 31, 2009 Across America Financial Services, Inc. (Across America) completed the acquisition of Apro Bio Pharmaceutical Corporation (Apro Bio) pursuant to the terms of the Agreement of Merger and Plan of Reorganization, as amended (the Merger) among Across America, Apro Bio and Across America Acquisition Corp. (AAAC), a Colorado corporation and a wholly-owned subsidiary of Across America. Under the terms of the Merger, AAAC was merged into Apro Bio, and Apro Bio became a wholly-owned subsidiary of the Company. On May 27, 2009 Across America changed its name to Omni Bio Pharmaceutical, Inc. (Omni). It intends to commercialize a broad patent portfolio licensed from the UCHSC, and a component of these applications involves use of existing FDA approved drugs to treat a variety of bacterial and viral diseases, biohazards and transplant rejection. It is the licensee of filed, but not yet issued, patents related to composition of matter and method of use for an existing FDA approved drug, Alpha 1 Antitrypsin (AAT), for treating organ transplantation, including islet transplantation for the treatment of diabetes and bacterial infections including bacterial pneumonia, tuberculosis and anthrax. It has also licensed an existing patent for the treatment of viral infection including HIV, influenza and potentially the 'bird flu' virus. The Company plans to acquire and develop existing and novel therapies that have the potential to move through clinical trials quickly, shepherd them through the FDA approval processes and advance them through commercialization. This approach is similar to what developed for the drug Minoxodil (trade named Rogaine(r)), which previously had come off its initial patents to treat high blood pressure. It faces intense competition from a range of pharmaceutical, biotechnology and diagnostic companies, as well as academic and research institutions and government agencies. Regulations in the U.S. and other countries would have a significant impact on its research, product development and manufacturing activities and would be a significant factor in the marketing of its products.
» More Articles for OMBP

Headlines

Articles On GuruFocus.com
Omni Bio to Present at Biotech Showcase 2015 Jan 06 2015 
Omni Bio Announces Encouraging Clinical Data for Use of Alpha-1 Antitrypsin (AAT) in Steroid-Resista Dec 09 2014 
Omni Bio Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association Sci Nov 19 2014 
Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic Nov 18 2014 

More From Other Websites
OMNI BIO PHARMACEUTICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 25 2015
OMNI BIO PHARMACEUTICAL, INC. Files SEC form 8-K, Other Events May 08 2015
OMNI BIO PHARMACEUTICAL, INC. Financials Mar 14 2015
OMNI BIO PHARMACEUTICAL, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Mar 13 2015
OMNI BIO PHARMACEUTICAL, INC. Files SEC form 10-Q, Quarterly Report Feb 17 2015
OMNI BIO PHARMACEUTICAL, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 02 2015
OMNI BIO PHARMACEUTICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jan 07 2015
Omni Bio to Present at Biotech Showcase 2015 Jan 06 2015
OMBP: Omni Bio's Hand Gets Stronger As AAT Shows Potential In GvHD Dec 11 2014
Omni Bio Announces Encouraging Clinical Data for Use of Alpha-1 Antitrypsin (AAT) in... Dec 09 2014
OMBP: Omni Bio Encouraged By Early-Stage Data At American Heart Association Meeting Nov 21 2014
Omni Bio Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association... Nov 19 2014
Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic Nov 18 2014
OMNI BIO PHARMACEUTICAL, INC. Files SEC form 10-Q, Quarterly Report Nov 14 2014
OMNI BIO PHARMACEUTICAL, INC. Files SEC form 8-K, Other Events Oct 20 2014
Omni Bio to Present at 7th Annual BioPharm America Conference Sep 16 2014
OMNI BIO PHARMACEUTICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Sep 11 2014
OMBP: Omni Bio Executing On Development Plan Aug 26 2014
OMNI BIO PHARMACEUTICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Aug 14 2014
Omni Bio Appoints Jack Riccardi as Chief Financial Officer Aug 14 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK